Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab as Adjunct to Grass SCIT for Allergic Rhinitis
NCT03558997Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of dupilumab in seasonal allergic rhinitis (SAR), sponsored by Regeneron Pharmaceuticals. Started Jun 2018; status: completed.
02
Drugs
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT03558997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03558997.